BioPharma BoardRoom

J.P. Morgan's new report highlights Innovative Trials' commitment to diversity and excellence, as it leads the way in patient recruitment and retention strategies for clinical trials, empowering women in STEM and achieving remarkable growth since its 2010 founding by Kate Shaw

"Our team delivered another quarter of solid financial results, including outperformance in bioprocessing and a return to growth in our laboratory solutions segment. Our disciplined approach to working capital drove another quarter of best-in-class free cash flow conversion and we are raising our free cash flow guidance for the year," said Michael Stubblefield, President and Chief Executive Officer Avantor

“We are pleased to deliver strong financial results in the third quarter, reflecting another quarter of sequential improvement in growth,” said Marc Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “We continue to deliver differentiated performance through our proven growth strategy and PPI Business System. Our trusted partner status is resonating strongly with customers, and this is translating into meaningful commercial wins.”

"We are pleased to strategically collaborate with the Asia-based pharmaceutical company to bring effective, high-quality biopharmaceuticals to the global market," said John Rim, President and CEO of Samsung Biologics. "The deal comes at a significant time as we proactively build on our biomanufacturing capacity to readily support our clients. Leveraging our capabilities and proven expertise, we plan to maintain momentum for further expansion by fostering trusted and sustainable partnerships with potential and existing clients for mutual growth, and ultimately help patients with unmet needs."

“Analytical lab managers face intense pressure to optimize operational efficiency without sacrificing result quality. With InfinityLab Assist, our customers can significantly reduce the time and effort spent on operator training, troubleshooting, and automating daily startup routines and system health notifications,” said Sudharshana Seshadri, vice president and general manager of Agilent Technologies’s Liquid Chromatography, Mass Spectrometry, and Automation divisions.  https://lnkd.in/dwE2P5kn

Catalent Pharma Solutions CEO John Chiminski Issues Open Letter Addressing Novo Holdings’ Acquisition and Reaffirms Commitment to Customers

@Dr. Christian Behrenbruch, Managing Director and Group Chief Executive Officer, Telix Pharmaceuticals Limited, emphasized the company’s advancements in its therapeutic pipeline, the upcoming commercialization of new imaging agents, and Telix's robust cash position to support future growth and infrastructure investment.

"Patients living with generalized myasthenia gravis deserve an effective treatment option that provides long-term symptom relief. Once approved, UPLIZNA is expected to offer a new option for patients earlier in their treatment plan," said Jay Bradner, M.D., executive vice president, Research and Development, and chief scientific officer at Amgen.

"By automating the complex library preparation process, researchers can scale their sample throughput and expect more consistent results, minimizing the variability introduced by manual procedures," said Steve Conly, worldwide president of BD Biosciences. "This standardization is crucial for the reproducibility of experiments, which is a cornerstone of scientific research. The integration of Hamilton's robotics with BD's robotics-ready reagent kits can streamline workflows, reduce the potential for human error, and accelerate the pace of discovery in critical areas such as oncology and immunology." Matt Hamilton CEO at Hamilton Robotics

  "Today marks a significant milestone in Ardena’s international growth strategy," explains Jeremie Trochu, Chief Executive Officer of Ardena. "We are thrilled to welcome the talented scientific and operations team from Somerset into the Ardena family. Their commitment to providing exceptional service aligns perfectly with our core values of excellence, reliability, care, and integrity. Together, we will continue to support biopharma companies at the cutting edge of innovation to deliver life-changing therapies to patients worldwide."